New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For BMY;PFE;DUF;CG;HLF;CALM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | all recent news | >>
April 9, 2015
09:51 EDTPFEPerrigo did not expect Mylan takeover letter, CNBC's Faber reports
Perrigo (PRGO) did not expect the takeover letter it received from Mylan (MYL), CNBC's David Faber reports, citing sources. Perrigo will take its time in deciding what its next steps are, Faber added. Shares of Mylan are up 3% in early trading, which is being attributed, at least in part, to speculation the company could be a takeover target itself. Analysts this morning mentioned Teva (TEVA) as a potential acquirer of Mylan. Chatter this morning has Pfizer (PFE) also potentially interested in the EpiPen maker
09:25 EDTPFEPiper Jaffray pharmaceuticals analysts hold an analyst/industry conference call
Subscribe for More Information
08:04 EDTPFEPfizer launches PCSK9 competitive grants program
Subscribe for More Information
07:05 EDTCALMCal-Maine Foods announces JV with Rose Acre Farms in Texas
Subscribe for More Information
April 8, 2015
08:08 EDTBMYuniQure price target raised to $50 from $28 at Leerink
Subscribe for More Information
08:06 EDTBMYBristol-Myers completes acquisition of Flexus Biosciences
Bristol-Myers Squibb Company announced that it has completed the previously announced planned acquisition of Flexus Biosciences, Inc. The transaction includes full rights to F001287, Flexus’ lead preclinical, small-molecule IDO1-inhibitor targeted for IND filing in the second half of 2015 and an IDO/TDO discovery program that includes its IDO-selective, IDO/TDO dual and TDO-selective compound libraries. A newly formed entity established by the current shareholders of Flexus will retain, from and after the closing, all non-IDO/TDO assets of Flexus including those related to Flexus’ Phase 1 FLT3 and CDK4/6 inhibitor, its earlier stage small-molecule Treg cancer immunotherapy programs, and its current personnel and facilities.
April 7, 2015
16:18 EDTCGOn The Fly: Closing Wrap
Stocks on Wall Street opened in positive territory, extending their gains from yesterday. The economic calendar was relatively quiet and the volume was light as investors moved to the sidelines ahead of the start of the first quarter earnings season, which kicks off tomorrow after the close with Alcoa's (AA) report. A late day slide saw the major averages give up their gains, leaving the Dow, Nasdaq and S&P 500 a bit below where they had started the day. ECONOMIC EVENTS: In the U.S., the JOLTs report showed job openings rose 168K to 5.13M in February, topping the consensus forecast for about 5M opening. Consumer credit climbed $15.5B in February, versus the expectation for consumers to have added $12.5B in new credit. In Europe, Markit's composite PMI for the eurozone came in at 54.0, which was down slightly from the flash reading of 54.1 but up from 53.3 in February and matched the prior peak seen in April of last year. Elsewhere globally, the central banks of Australia and India left their respective key interest rates unchanged, as expected. COMPANY NEWS: Shares of FedEx (FDX) advanced $4.49, or 2.69%, to $171.16 after the shipper announced a conditional deal to acquire TNT Express (TNTEY) for EUR 8.00 per share in a transaction valuing the Netherlands-based express delivery company at an implied equity value of about $4.8B. The company hopes it is more successful in its acquisition attempt than rival UPS (UPS), which had agreed a number of years ago to buy TNT for EUR 9.50 per share. UPS pulled out of its planned purchase after its proposed deal for TNT was blocked by regulators. MAJOR MOVERS: Among the notable gainers was Axalta Coating Systems (AXTA), which gained $2.78, or 9.81%, to $31.11 after an affiliate of Warren Buffett's Berkshire Hathaway (BRK.A) agreed to buy 20M of Axalta’s common shares for an aggregate purchase price of $560M, or $28.00 per share, from The Carlyle Group (CG). Also higher was Informatica (INFA), which advanced $1.96, or 4.28%, to $47.79 after agreeing to be acquired by the Permira funds and Canada Pension Plan Investment Board for approximately $5.3B, or $48.75 in cash per share. The official announcement follows recent stories from Reuters that the company was working on a deal with a private equity buyer. Among the noteworthy losers was Ocular Therapeutix (OCUL), which dropped $7.25, or 18.93%, to $31.05 after reporting that the company’s second of two Phase 3 clinical trials evaluating the safety and efficacy of its lead product candidate, OTX-DP, met only one of the study’s two primary efficacy endpoints. Also lower were shares of Woodward (WWD), which fell $3.06, or 5.95%, to $48.36 after Jefferies downgraded the stock to Hold from Buy and set a $52 price target on the shares, saying FY15 is another transition year for the company. INDEXES: The Dow slipped 5.43, or 0.03%, to 17,875.42, the Nasdaq lost 7.08, or 0.14%, to 4,910.23, and the S&P 500 declined 4.29, or 0.21%, to 2,076.33.
15:53 EDTCGMicrosoft, Getty Images announce partnership to develop products for Bing
Subscribe for More Information
15:48 EDTCGMicrosoft, Getty Images dismiss copyright infringement dispute, Reuters says
Subscribe for More Information
08:09 EDTPFEPfizer, Merck KGaA finalize agreement to co-promote XALKORI
Merck KGaA (MKGAY) and Pfizer (PFE) announced the finalization of the co-promotion agreement allowing the companies to co-promote Pfizer’s anaplastic lymphoma kinase inhibitor XALKORI. Under the agreement, XALKORI will be co-promoted in two waves, the first of which will begin in the second and third quarters of 2015 in the United States, Canada, Japan and five European Union countries: France, Germany, Italy, Spain and the United Kingdom. In the U.S. and Canada, XALKORI will be co-promoted by EMD Serono, the U.S. and Canadian biopharmaceutical businesses of Merck KGaA. The second wave will begin in 2016 and includes China and Turkey. n 2015, Merck KGaA will receive a reimbursement associated with its promotion of XALKORI, followed by an 80% for Pfizer, 20% for Merck KGaA profit sharing on the product starting in 2016. The co-promotion term will last through December 31, 2020 for the U.S., Canada, Japan, France, Germany, Italy, Spain and the U.K. and from January 1, 2016 through December 31, 2021 in China and Turkey. Pfizer will report the sales of XALKORI in countries where it is co-promoted with Merck KGaA.
08:01 EDTHLFHerbalife announces one-year partnership with Global Health Strategies Institute
Herbalife announced a one-year partnership with Global Health Strategies Institute to help improve the nutrition of more than 10,000 children ages 5-12 in India, in line with the government’s Mid-Day Meal Scheme and School Health Programs. As part of its corporate social responsibility efforts, Herbalife will work with GHSI and global vitamin supplier DSM, to help provide access to good nutrition to children in India, a country with a history of malnourished, underweight children. The government-run MDMS and SHP programs are designed to improve the nutritional needs of children by providing food supplemented with adequate quantities of iron, folic acid and vitamin A. However, more fortified foods with essential micronutrients are needed. In the first phase of the project, GHSI will conduct a landscape analysis to help all parties understand the nutritional landscape, provide insights into the required nutritional support, the target beneficiaries, expected reach, implementation model and potential partners.
07:18 EDTCGAxalta Coating announces sale of shares to Berkshire Hathaway
Subscribe for More Information
07:14 EDTBMY, PFEEyeforpharma to hold a summit
Philadelphia 2015 Commercial Pharma Summit is being held in Philadelphia on April 7-8.
07:02 EDTPFEGlycoMimetics updates on Pfizer's plans to initiate Phase 3 Rivipansel trial
Subscribe for More Information
05:55 EDTHLFStocks with implied volatility movement; MNKD HLF
Stocks with implied volatility movement; MannKind (MNKD) 68, Herbalife (HLF) 89 according to iVolatility.
April 6, 2015
19:49 EDTHLFHerbalife implements online ordering, LA Times says
Subscribe for More Information
16:17 EDTBMYOn The Fly: Closing Wrap
Subscribe for More Information
12:44 EDTBMYOn The Fly: Midday Wrap
Subscribe for More Information
12:13 EDTBMYuniQure price target raised to $40 from $35 at Piper Jaffray
Subscribe for More Information
10:37 EDTPFETargacept says Pfizer terminates research & license agreement with Catalyst
In a regulatory filing from earlier, Targacept (TRGT) said: "As previously reported, on March 5, Targacept, Talos Merger Sub, a Delaware corporation and a wholly owned subsidiary of Targacept and Catalyst Biosciences, entered into an Agreement and Plan of Merger, pursuant to which, among other things, subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub will merge with and into Catalyst, with Catalyst becoming a wholly owned subsidiary of Targacept and the surviving corporation of the merger. On April 1, Catalyst notified Targacept that Pfizer (PFE) would be exercising its right to terminate in its entirety the June 29, 2009, research and license agreement between Catalyst and Wyeth, which governs the development and commercialization of Catalyst’s leading human Factor VIIa product candidate for the treatment of hemophilia and surgical bleeding indications. On April 2, Pfizer provided Catalyst with its formal written notice of termination of the research and license agreement. Upon the June 1, effective date of the termination, the license and certain rights under the research and license agreement will terminate and revert to Catalyst. Catalyst has informed Targacept that Pfizer is committed to an orderly transfer of data, regulatory documentation and related technology under the agreement to Catalyst to enable Catalyst to continue the clinical development of this product candidate. Targacept is currently reviewing the implications of this event on the proposed Merger. In morning trading shares of Targacept are down almost 12% to $2.51.
<< 1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use